Litcius/Paper detail

Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial

Hongyan Cheng, Liju Zong, Yujia Kong, Xiaoyu Wang, Yu Gu, Wei Cang, Jun Zhao, Xirun Wan, Junjun Yang, Yang Xiang

2021The Lancet Oncology82 citationsDOI

Topics & Concepts

ApatinibGestational trophoblastic neoplasiaMedicineOncologyOpen labelObstetricsInternal medicineChemotherapyClinical trialOverall survivalGestational Trophoblastic Disease StudiesMaternal and fetal healthcareEctopic Pregnancy Diagnosis and Management
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial | Litcius